Welcome to our dedicated news page for Myriad Genetics (Ticker: MYGN), a resource for investors and traders seeking the latest updates and insights on Myriad Genetics.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Myriad Genetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Myriad Genetics's position in the market.
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) has completed the acquisition of select assets from Intermountain Health, including the Precise™ Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory in St. George, Utah. The Precise Tumor Test analyzes a patient’s tumor DNA to discover and target important variants within tumors, while Precise Liquid will provide comprehensive genomic profiling results from a blood draw. This acquisition allows Myriad to expand its tumor profiling offerings and complement its oncology portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
-
News
Rhea-AI Summary
Myriad Genetics, Inc. appoints George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings over 30 years of experience in oncology and precision medicine. His role involves leading the commercial and clinical strategy to advance Myriad’s oncology portfolio, including germline testing, tumor profiling, and companion diagnostic options. The company plans to expand its product offerings into liquid biopsy and minimal residual disease (MRD) testing. Dr. Daneker's appointment is expected to accelerate Myriad's strategy with health systems and large oncology practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.98%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. has announced the acquisition of select assets from Intermountain Precision Genomics’ laboratory business, including the Precise™ Tumor Test and the Precise Liquid Test. The acquisition is expected to close on February 1, 2024, and aims to enhance Myriad's commitment to its oncology business and provide new opportunities for innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
Rhea-AI Summary
Myriad Genetics, a leader in genetic testing and precision medicine, announces support for the ASCO-SSO guideline for germline testing in patients with breast cancer. The guideline recommends BRCA1/2 testing for patients with invasive breast cancer, as well as testing for other breast cancer genes to inform medical therapy and surgical decision-making.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) to present at 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024. The presentation will be available through a live webcast on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) appoints Scott Leffler as the new Chief Financial Officer, effective January 29, 2024, succeeding Bryan Riggsbee. Leffler brings 20 years of finance experience and will lead the company's financial team and strategy to support long-term growth and profitability. Myriad reiterates its 2023 financial guidance and introduces 2024 revenue guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) launches the Myriad Collaborative Research Registry (MCRR), a pan-cancer registry with data from over one million patients. The registry aims to support transparent clinical data sharing, advance precision cancer research, and provide a secure platform for scientific data analysis and collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) has delivered results to one million consumers with its SneakPeek® Early Gender DNA Test, offering expectant families an easy way to learn the sex of their baby as early as six weeks into pregnancy. The test is 99% accurate and can be taken at home or at a local clinic, with results shared as early as the same day through email. Myriad Genetics acquired Gateway Genomics, the developer of SneakPeek, expanding its reproductive health testing solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
-
Rhea-AI Summary
Myriad Genetics, Inc. (Nasdaq: MYGN) and Personalis, Inc. (Nasdaq: PSNL) have announced a collaboration to introduce the Personalis® ImmunoID NeXT platform to Myriad's pharmaceutical partners using their cancer tests. This collaboration aims to provide whole exome and whole transcriptome testing on patients' tumors, expanding Myriad's service offering. The ImmunoID NeXT platform is utilized by top global bio-pharma companies and offers high-quality exome/transcriptome assays for cancer FFPE samples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.83%
Tags
Rhea-AI Summary
Myriad Genetics, Inc. (NASDAQ: MYGN) to participate in Stephens Annual Investment Conference for a fireside chat on November 15 at 2:00 p.m. ET. Live and archived webcast available on www.myriad.com
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.94%
Tags
Myriad Genetics Inc
Nasdaq:MYGN
MYGN Rankings
MYGN Stock Data
1.76B
74.68M
2.01%
103.03%
6.3%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SALT LAKE CITY
About MYGN
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.